Weekly Research Analysts’ Ratings Updates for Promis Neurosciences (PMN)

A number of research firms have changed their ratings and price targets for Promis Neurosciences (NASDAQ: PMN):

• 6/11/2026 – Promis Neurosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/9/2026 – Promis Neurosciences was upgraded by Zacks Research to “hold”.
• 6/8/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 5/31/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/20/2026 – Promis Neurosciences was upgraded by Brookline Capital Markets to “strong-buy”.

Insiders Place Their Bets

In other news, Director Patrick D. Kirwin acquired 4,000 shares of Promis Neurosciences stock in a transaction that occurred on Wednesday, April 22nd. The shares were bought at an average cost of $11.33 per share, with a total value of $45,320.00. Following the transaction, the director directly owned 4,653 shares of the company’s stock, valued at $52,718.49. This trade represents a 612.56% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.50% of the stock is owned by company insiders.

Promis Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small?molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.